New Immunotherapy Combination for Advanced Melanoma
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs (cadonilimab and interferon) given before surgery to treat advanced melanoma that has spread to nearby lymph nodes or one distant site. The goal is to shrink tumors and improve chances of successful surgery and long-term survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 with confirmed melanoma that is stage III (spread to lymph nodes) or resectable stage IV (one removable distant tumor, no brain tumors)
- No previous treatment with similar immunotherapy drugs (PD-1, PD-L1, CTLA-4 inhibitors), interferon, chemotherapy, or radiation in the past month
- Generally good health (able to be up and about most of the day) with expected survival of at least 6 months
- Normal or near-normal blood counts, kidney, and liver function within 4 weeks before starting treatment
- If female and able to have children: negative pregnancy test and agreement to use contraception for 12 months after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (iSCIB1+) combined with two standard immunotherapy drugs (ipilimumab and nivolumab) as the first treatment for advanced melanoma that cannot be removed by surgery. The goal is to see if adding iSCIB1+ helps the immune system fight the cancer better.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests a combination of three drugs (interferon, an immunotherapy drug called toripalimab, and an anti-cancer drug called anlotinib) in people with advanced melanoma that cannot be removed with surgery. The goal is to see if this combination can help shrink or control the cancer.
This trial tests two new drugs (cadonilimab and anlotinib) for people with melanoma that has spread or grown after their first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of immunotherapy treatments for advanced melanoma that has not responded to standard therapy. The goal is to use your own immune cells to fight the cancer more effectively.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.